



# HHS Public Access

Author manuscript

*Clin Pharmacol Ther.* Author manuscript; available in PMC 2017 August 02.

Published in final edited form as:

*Clin Pharmacol Ther.* 2012 November ; 92(5): 535–537. doi:10.1038/clpt.2012.151.

## Advancing Pharmacometrics and Systems Pharmacology

SA Waldman<sup>1</sup> and A Terzic<sup>2</sup>

<sup>1</sup>Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

<sup>2</sup>Divisions of Cardiovascular Diseases and Clinical Pharmacology, Departments of Medicine, Molecular Pharmacology, and Experimental Therapeutics and Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA

### Abstract

Pharmacometrics and systems pharmacology are emerging as principal quantitative sciences within drug development and experimental therapeutics. In recognition of the importance of pharmacometrics and systems pharmacology to the discipline of clinical pharmacology, the American Society for Clinical Pharmacology and Therapeutics (ASCPT), in collaboration with Nature Publishing Group and *Clinical Pharmacology & Therapeutics*, has established *CPT: Pharmacometrics & Systems Pharmacology* to inform the field and shape the discipline.

The concept that dose differentiates a medicine from a poison is the nucleus from which clinical pharmacology has emerged as a science and practice.<sup>1</sup> This conceptual singularity has provided an organizing principle anchored in quantitative theory that defines the scope of this translational discipline.<sup>2</sup> It has produced the cornerstones of the field, including pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body).<sup>2</sup> Deriving from these core concepts, clinical pharmacology emerged as a discipline focused largely on developing tools and models to define fundamental relationships to predict therapy vs. toxicology.<sup>1,2</sup> From these quantitative underpinnings, the revolution in the new biology, associated with the availability of enabling discovery platforms, in conjunction with the advent of increasingly more sophisticated statistical modeling approaches that deconvolute complex networks of information, offers the next evolutionary step for the discipline.<sup>3,4</sup> Indeed, innovations in biology, statistics, and engineering have provided an opportunity to define the effects of drugs beyond a single molecular target, namely, to their impact on entire systems of integrated signaling networks and biological processes.<sup>5,6</sup> In turn, systems pharmacology provides higher-order dimensionality to drug actions that more precisely informs statistical models predicting concentration–response relationships, defining the framework for the nascent field of pharmacometrics central to enhancing drug development, regulation, and utilization.<sup>3,7–9</sup>

The emergence of systems pharmacology and pharmacometrics as principal quantitative sciences within clinical pharmacology has been associated with the development of highly

Correspondence: SA Waldman (scott.waldman@jefferson.edu) or A Terzic (terzic.andre@mayo.edu).

**Conflict of Interest:** The authors declared no conflict of interest.

specialized techniques and approaches in molecular biology, engineering, and modeling central to the practice of these subspecialties.<sup>3,6,7,10</sup> Indeed, systems biology provides an emerging platform that integrates complex interactions defining health and disease.<sup>11</sup> Co-application of network medicine and pharmacology science for rational drug discovery and development has offered an unprecedented toolkit propelling most modern efficacy and safety algorithms.<sup>5</sup> Moreover, next-generation vocabularies integrate pharmacology, clinical medicine, computer sciences, mathematics, quantitative biology, and systems engineering to communicate concepts and experimental results that define the vanguard of these fields.<sup>1,5</sup> In that context, the successful evolution of systems pharmacology and pharmacometrics is predicated on the nurturing of these disciplines. In turn, nurturing requires a forum where these communities can exchange and develop techniques, standards of practice, applications, and innovations, employing the lexicon and applying the concepts that define these subspecialties.

In recognition of the burgeoning importance of pharmacometrics and systems pharmacology to the discipline of clinical pharmacology, the American Society for Clinical Pharmacology and Therapeutics (ASCPT), in collaboration with Nature Publishing Group and *Clinical Pharmacology & Therapeutics*, has established *CPT: Pharmacometrics & Systems Pharmacology*.<sup>12</sup> The objective of this open-access journal is to create a dedicated forum for the exchange of information essential to the practice of these emerging disciplines. The creation of this journal recognizes the importance of a dedicated venue for the advancement of specialized models, technologies, and concepts forming the frameworks central to these communities of practice. It anticipates a need for public debate and discourse in these fields to catalyze evolution and the development of best practices. Importantly, this journal creates an opportunity for community dialogue employing the specialized lexicon and concepts that at once define these fields and set them apart from other communities of practice within clinical pharmacology.

*Clinical Pharmacology & Therapeutics* welcomes *CPT: Pharmacometrics & Systems Pharmacology* as the latest addition to the ASCPT publication family. It is anticipated that these journals will work collaboratively to advance the subspecialties of systems pharmacology and pharmacometrics, and the discipline of clinical pharmacology as a whole. We expect that manuscripts reporting studies using systems pharmacology or pharmacometrics as tools to define key issues with broad applicability in clinical pharmacology, therapeutics, and health care will be best suited for publication in *Clinical Pharmacology & Therapeutics*. By contrast, papers focusing on issues that are the specific province of systems pharmacology or pharmacometrics may be best suited for *CPT: Pharmacometrics & Systems Pharmacology*. The editorial leadership of the journals and their editorial boards will work cooperatively to ensure that the highest-quality science is targeted to the most appropriate audience. Additionally, *Clinical Pharmacology & Therapeutics* and *CPT: Pharmacometrics & Systems Pharmacology* will work together to enhance the dissemination of advances in clinical pharmacology, systems pharmacology, and pharmacometrics through programming at annual meetings and symposia. *Clinical Pharmacology & Therapeutics* looks forward to a productive collaboration with *CPT: Pharmacometrics & Systems Pharmacology* in this next step in the evolution of the discipline of human therapeutics.

## Acknowledgments

This work was supported by the National Institutes of Health Grants 1R01 CA170533 and P30 CA56036 to S.A.W

## References

1. Atkinson AJ Jr, Lyster PM. Systems clinical pharmacology. *Clin Pharmacol Ther.* 2010; 88:3–6. [PubMed: 20562885]
2. Atkinson AJ Jr, Smith BP. Models of physiology and physiologically based models in clinical pharmacology. *Clin Pharmacol Ther.* 2012; 92:3–6. [PubMed: 22713729]
3. Grasel TH, Slusser R. Improving productivity with model-based drug development: an enterprise perspective. *Clin Pharmacol Ther.* 2010; 88:263–268. [PubMed: 20592720]
4. Kohl P, Crampin EJ, Quinn TA, Noble D. Systems biology: an approach. *Clin Pharmacol Ther.* 2010; 88:25–33. [PubMed: 20531468]
5. Arrell DK, Terzic A. Network systems biology for drug discovery. *Clin Pharmacol Ther.* 2010; 88:120–125. [PubMed: 20520604]
6. Rodriguez B, Burrage K, Gavaghan D, Grau V, Kohl P, Noble D. The systems biology approach to drug development: application to toxicity assessment of cardiac drugs. *Clin Pharmacol Ther.* 2010; 88:130–134. [PubMed: 20520607]
7. Allerheiligen SR. Next-generation model-based drug discovery and development: quantitative and systems pharmacology. *Clin Pharmacol Ther.* 2010; 88:135–137. [PubMed: 20531467]
8. Dollery CT. The challenge of complexity. *Clin Pharmacol Ther.* 2010; 88:13–15. [PubMed: 20562888]
9. Vicini P. Multiscale modeling in drug discovery and development: future opportunities and present challenges. *Clin Pharmacol Ther.* 2010; 88:126–129. [PubMed: 20520608]
10. Yang R, Niepel M, Mitchison TK, Sorger PK. Dissecting variability in responses to cancer chemotherapy through systems pharmacology. *Clin Pharmacol Ther.* 2010; 88:34–38. [PubMed: 20520606]
11. Waldman SA, Terzic A. Molecular therapeutics from knowledge to delivery. *Clin Pharmacol Ther.* 2010; 87:619–623. [PubMed: 20485312]
12. van der Graaf PH. CPT: Pharmacometrics and Systems Pharmacology. *CPT Pharmacometrics Syst Pharmacol.* 2012; 1:e8. [PubMed: 23835888]